Tibet Rhodiola Pharmaceutical Holding Co. (SHA:600211)

SHA:600211 Revenue

Tibet Rhodiola Pharmaceutical Holding Co. had revenue of 621.59M CNY in the quarter ending September 30, 2026, with 41.73% growth. This brings the company's total for the last twelve months to 3.07B, up 12.78% year-over-year. In the year 2025, Tibet Rhodiola Pharmaceutical Holding Co. had annual revenue of 2.98B with 6.23% growth. That makes Tibet Rhodiola Pharmaceutical Holding Co. the 11,742nd largest company in the world by revenue and 1,999th in China.

• Revenue (ttm): 3.07B
• Revenue Growth: +12.78%
• P/S Ratio: 4.19
• Revenue / Employee: 4.57M
• Employees: 671
• Market Cap: 12.85B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Pharmaceutical Business 2.82B 58.6%
• Medicine Manufacturing 1.99B 41.3%
• Other 2.64M 0.1%

By Geography

Chart

• China 2.89B 97.1%
• Overseas 87.76M 2.9%

Fiscal year ended Dec 31, 2025 See the full SHA:600211 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	2.98B	174.82M	6.23%
Dec 31, 2024	2.81B	-327.62M	-10.45%
Dec 31, 2023	3.13B	579.72M	22.69%
Dec 31, 2022	2.55B	416.02M	19.45%
Dec 31, 2021	2.14B	765.48M	55.75%

Data Source: S&P Global Market Intelligence Last updated: Oct 30, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 6, 2026

Data Sources Report a data error